A U.S. bankruptcy judge ruled that California's appeal to block the deal was unlikely to succeed, rejecting claims that the sale violated state genetic privacy laws.
The deal encompasses 23andMe’s core genome testing service, research operations, and Lemonaid Health, with TTAM set to relaunch the company as a nonprofit organization committed to upholding existing data privacy policies.